Bioventus Inc. $BVS Shares Bought by Royce & Associates LP

Royce & Associates LP grew its holdings in shares of Bioventus Inc. (NYSE:BVS) by 15.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,262,976 shares of the company’s stock after purchasing an additional 170,900 shares during the period. Royce & Associates LP owned approximately 1.53% of Bioventus worth $8,449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after buying an additional 1,538 shares in the last quarter. Covestor Ltd lifted its stake in shares of Bioventus by 28.0% in the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after acquiring an additional 2,176 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Bioventus by 28.3% in the second quarter. The Manufacturers Life Insurance Company now owns 17,855 shares of the company’s stock valued at $118,000 after acquiring an additional 3,935 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Bioventus by 55.9% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,768 shares of the company’s stock valued at $78,000 after acquiring an additional 4,221 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Bioventus by 4.6% during the second quarter. Franklin Resources Inc. now owns 131,149 shares of the company’s stock valued at $868,000 after acquiring an additional 5,748 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Barrington Research initiated coverage on Bioventus in a research report on Monday, February 9th. They issued an “outperform” rating and a $13.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.75.

Insider Buying and Selling at Bioventus

In related news, Director Guy P. Nohra sold 10,000 shares of Bioventus stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $7.57, for a total value of $75,700.00. Following the transaction, the director directly owned 116,610 shares in the company, valued at $882,737.70. The trade was a 7.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 33.00% of the stock is currently owned by corporate insiders.

Bioventus Trading Down 0.3%

Shares of NYSE:BVS opened at $8.74 on Wednesday. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a market capitalization of $723.35 million, a price-to-earnings ratio of -14.33 and a beta of 0.80. Bioventus Inc. has a 1-year low of $5.81 and a 1-year high of $11.25. The company has a 50 day moving average price of $8.05 and a 200 day moving average price of $7.47.

Bioventus Profile

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.